Skip to main content
Lyka Labs Ltd. logo

Lyka Labs Ltd. — Investor Relations & Filings

Ticker · LYKALABS ISIN · INE933A01014 LEI · 3358001RHQJBCTT1ER45 BSE.NS Manufacturing
Open in API
Filings indexed 1,205 across all filing types
Latest filing 2025-02-05 Regulatory Filings
Country IN India
Listing BSE.NS LYKALABS

About Lyka Labs Ltd.

https://www.lykalabs.com

Lyka Labs Ltd. specializes in the development, manufacture, and marketing of pharmaceutical formulations and active pharmaceutical ingredients (APIs). The company maintains a diverse product portfolio spanning multiple therapeutic categories, including anti-infectives, dermatologicals, cardiovascular agents, and pain management. A significant area of expertise for the organization is lyophilization technology, enabling the production of high-quality injectable formulations. The company operates advanced manufacturing facilities designed to meet international quality standards, supporting its operations in both domestic and global markets. Its core activities encompass the production of various dosage forms such as tablets, capsules, ointments, and sterile injectables, with a particular focus on specialized segments like cephalosporins and critical care medications.

Recent filings

Filing Released Lang Actions
As per letter attached
Regulatory Filings
2025-02-05 English
Financial Result Updates
Regulatory Filings
2025-02-04 English
Outcome of Board Meeting
Regulatory Filings Classification · 95% confidence The document is a formal communication from the company to stock exchanges reporting the outcome of a Board Meeting held on 4th March 2025. It specifically mentions the approval of unaudited standalone and consolidated financial results for the quarter and nine months ended 31st December 2024. It also references the Limited Review Reports of the Auditors. The document is short (1631 characters) and serves as an announcement of the financial results and the board meeting outcome rather than the full financial report itself. According to the 'Menu vs Meal' rule, such announcements are classified as Regulatory Filings (RNS) because they notify about the results and include limited review reports but do not contain the full financial statements or detailed analysis typical of an Interim/Quarterly Report (IR).
2025-02-04 English
As per letter attached
Regulatory Filings
2025-02-04 English
As per letter attached
Regulatory Filings
2025-02-04 English
Copy of Newspaper Publication
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges (BSE and NSE) regarding the publication of notices for meetings of shareholders and creditors as per an order of the National Company Law Tribunal (NCLT). It references Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and mentions the publication of notices in newspapers. The content is about announcing the scheduling and publication of meeting notices, not the meeting materials themselves or the results of votes. The document is about the announcement of notices for meetings, which is a regulatory announcement related to compliance and disclosure requirements. It does not contain financial statements, management discussion, voting results, or other detailed report content. The document length is about 15,000 characters, but the content is primarily an announcement of notices published in newspapers as per a tribunal order. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for general regulatory announcements and compliance documents that do not fit other specific categories.
2025-01-31 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.